MS Pharma Secures Growth Investment from Olayan Financing Company to Expand Operations

MS Pharma's Major Step Towards Growth

In a significant strategic move, MS Pharma, a prominent pharmaceutical company based in Jordan, has announced a minority equity investment from Olayan Financing Company (OFC). This partnership marks an important milestone, strengthening MS Pharma's growth trajectory in the MENA region and beyond. The announcement was made on May 18, 2026, highlighting a collaboration that not only promises innovation but also emphasizes a commitment to regional expansion and long-term value creation.

The investment deal includes MS Pharma issuing new shares in exchange for a substantial cash influx from OFC, allowing the latter to acquire a minority stake in the company. This partnership is poised to bolster MS Pharma's financial health and improve its capacity to meet ambitious growth targets across the MENA area. The resources provided will support the company in enhancing its biosimilar portfolio, manufacturing capabilities, and supply chain resilience, which are crucial for catering to the needs of patients, healthcare providers, and partners throughout the region.

Strengthening Capabilities Through Strategic Collaboration

Ghiath Sukhtian, the Chairman of MS Pharma, expressed enthusiasm about this new partnership with OFC. He remarked, "We are delighted and honored to welcome OFC as partners in the company. Their global operational and investing expertise, as well as their deep roots in KSA, will add significant value to MS Pharma and benefit all our stakeholders." His sentiments were echoed by Kalle Kaend, CEO of MS Pharma, who emphasized the pivotal moment this investment represents for the company, stating, "This investment comes at an exciting inflection point for MS Pharma. It will enable us to deepen our expertise in biologics, expand our reach in KSA and the wider MENA region, and accelerate our growth in biosimilars."

A Context of Excellence and Growth

With OFC's involvement, MS Pharma aims to tap into new resources and networks that can propel its operational efficiency and market presence. OFC's CEO, Nabeel Al-Amudi, highlighted the potential for this partnership to facilitate MS Pharma's expansion plans in Saudi Arabia and the larger MENA region, aligning perfectly with OFC's long-term investment ethos. Furthermore, this collaboration builds upon MS Pharma's leadership in producing biosimilars, particularly notable within KSA, where its biologics production facility holds the distinction of being the first to secure SFDA GMP approval for biologics manufacturing.

The company's strategy is finely tuned to localize its operations in line with the Saudi National Biotechnology Strategy and Vision 2030 initiatives. By aiming to become the first supplier of locally manufactured biologics to the Saudi market this year, MS Pharma reinforces its dedication to delivering high-quality healthcare solutions in the region. The company is not only focused on enhancing its domestic capabilities but is also looking to establish collaborations with global development and licensing partners to support international market exports.

About MS Pharma and Olayan Financing Company

MS Pharma stands as a leading pharmaceutical entity in the MENA region, characterized by its comprehensive approach to developing, producing, and distributing an extensive range of generic and biologic therapies. With five manufacturing facilities across pivotal locations, including Jordan, Algeria, and Saudi Arabia, MS Pharma is strategically positioned for accelerated growth. The company's headquarters in Amman, Jordan, supports a workforce of over 2,000 professionals across 12 countries.

Olayan Financing Company, established in 1947, is a key player in the investment landscape with a diverse portfolio spanning more than 32 companies. Its long-term investments range from public equities to private equities, strategically positioning OFC at the forefront of economic development goals in the context of Saudi Arabia's Vision 2030, with a focus on job creation, local talent development, and sustainability initiatives.

As MS Pharma continues on this trajectory of growth, the partnership with Olayan Financing Company is set to pave the way for innovative healthcare solutions in the region and contribute positively to its economic landscape.